Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 34Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Solid Tumor 7Rectal Neoplasms 7Lymphoma 7Glioblastoma 7Carcinoma, Hepatocellular 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Hodgkin Disease 6Colorectal Neoplasms 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Breast Neoplasms, Male 6Stomach Neoplasms 5Sarcoma 5Neuroendocrine Tumors 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Transitional Cell 5Thyroid Neoplasms 4Ovarian Neoplasms 4

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × Fluorodeoxyglucose F18 × Clear all
NCT00346125 2022-12-15

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
70 enrolled
Sarcoma

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡